生物活性 CB-839 (Telaglenastat) 是一种有效的,选择性的,口服生物可利用的 glutaminase 抑制剂,对重组人GAC的 IC50 为 24 nM。CB-839(Telaglenastat)可诱导自噬并具有抗肿瘤活性。[1] In Vitro CB-839表现出时间依赖性和缓慢可逆的动力学特性。与rHu-GAC预培养1小时后,CB-839抑制谷氨酰胺酶的IC50值<50...
CB-839 (Telaglenastat) 是一种有效的,选择性的 glutaminase 抑制剂,对重组人GAC的 IC50 为 24 nM。CB-839(Telaglenastat)可诱导自噬并具有抗肿瘤活性。 Biochemical mechanism: Cell permeable: yes Primary Target GLS1 Reversible: yes Target IC50: 23 nM & 28 nM, respectively, using murine kidney and...
CB-839 是一种有效的,选择性的,口服生物可利用的 glutaminase 抑制剂,对重组人GAC的 IC50 为 24 nM。Phase 1。 体外研究 CB-839 exhibits time-dependent and slowly reversible kinetics. IC50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for-1 hour are < 50 nmol/...
(2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13: 890-901.Gross MI, Demo SD, Dennison JB, Chen L, Chernov‑Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J...
CB-839, Web 英文网站:CB-839 中文网站:CB-839 CB-839产品描述:CB-839 is a potent, selective, and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC); inhibits recomb
英文名称Telaglenastat (CB-839) 生化机理Telaglenastat (CB-839)是一种强效、选择性和口服生物可用性谷氨酰胺酶抑制剂,对重组人谷氨酰胺酶的 IC50 值为 24 nM。CB-839(Telaglenastat)可诱导自噬,具有抗肿瘤活性。第一阶段 储存温度-80℃储存
CB-839 是一种高效的,可口服的 glutaminaseKGA和GAC的抑制剂,在肾脏和大脑的 glutaminase 的IC50值分别为 23 nM 和 28 nM。 CB-839名称 英文名CB-839 英文别名更多 CB-839生物活性 描述Telaglenastat (CB-839) 是可口服,非竞争性的谷氨酰胺酶1 (glutaminase 1 (GLS1)) 剪接变体 KGA 和 GAC 的抑制剂...
Telaglenastat (CB-839) (200 mg/kg; p.o.; twice daily for 28 days) has antitumor activity in xenograft models of TNBC[1]. 参考文献: [1]. Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890...
telaglenastat (cb 839) is a glutaminase 1 (gls1) inhibitor with selective, reversible, and oral activity. telaglenastat has antitumor activity and induces cellular autophagy. 价格:￥电议型 号:T6797产 地:中国大陆 1共1页 快速导航 企业档案 ...
The glutaminase inhibitor, telaglenastat (CB-839), has been tested in Phase I/II cancer trials and is well tolerated by patients. This study investigated if telaglenastat enhances the cellular response to IR in HNSCC models. Using three human HNSCC cell lines and two xenograft mouse models,...